Nektar Therapeutics Enters Oversold Territory (NKTR)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100. A stock is considered to be oversold if the RSI reading falls below 30.

In trading on Friday, shares of Nektar Therapeutics ( NKTR) entered into oversold territory, hitting an RSI reading of 29.6, after changing hands as low as $9.44 per share. By comparison, the current RSI reading of the S&P 500 ETF (SPY) is 66.3. A bullish investor could look at NKTR's 29.6 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. The chart below shows the one year performance of NKTR shares:

Find out what 9 other oversold stocks you need to know about »

Nektar Therapeutics 1 Year Performance Chart

Looking at the chart above, NKTR's low point in its 52 week range is $5.65 per share, with $11.34 as the 52 week high point — that compares with a last trade of $9.64.

According to the ETF Finder at ETF Channel, NKTR makes up 1.38% of the SPDR S&P Pharmaceuticals ETF ( XPH) which is trading higher by about 0.6% on the day Friday.

If you liked this article you might like

Canadian Pharma Goes Before FDA Panel Wednesday on Tamper Resistant Opioid

Biotech Movers: NeuroDerm Shares Soar on Sale to Japanese Firm

Puma Up as Breast Cancer Program Gets Green Light; Nektar's Oxycodon Comp. Gets Praise

Nektar Shares Boosted by Promising Results on Opioid Addiction Study

Apple Could Explode Higher to $200 a Share If This Chart Pattern Is Correct